Werewolf Therapeutics, Inc. (HOWL)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Discovery and Development of Cancer Therapeutics	19.94M	16.40M	-
Discovery and Development of Cancer Therapeutics Growth	21.60%	-	-
Total	19.94M	16.40M	-
Total Growth	21.60%	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States	19.94M	16.40M	-
United States Growth	21.60%	-	-
Total	19.94M	16.40M	-
Total Growth	21.60%	-	-

Source: S&P Global Market Intelligence.